logo-loader
viewCanntab Therapeutics Ltd

Canntab Therapeutics eyeing sales of its hard pills this summer as it strikes purchase deal with MediPharm Labs

Canntab said it was kicking off production of its instant release tablets today and already received its first order under the deal with MediPharm

Canntab Therapeutics Ltd -
The exact value of shipments under the agreement will be determined no later than June 30 this year, but is expected to top C$1 million

Canntab Therapeutics Ltd (CSE:PILL.CN) (OTCQB:CTABF) announced a major milestone Tuesday, striking a purchase deal with MediPharm (TSE:LABS)(OTCQX:MEDIF), which will start distributing and selling the former's cannabinoid tablets across Canada this summer.

Canntab said it was kicking off production of its instant release tablets today and already received its first order under the deal with MediPharm.

READ: Canntab Therapeutics appoints pharmaceutical scientist as new CSO

The exact value of shipments under the agreement will be determined no later than June 30 this year, but is expected to top C$1 million, the firm said in a statement.

"We are especially pleased to have accomplished this major milestone in the face of the Covid-19 Pandemic which has caused major uncertainty and disruption in world markets, including, Canada," said Jeff Renwick, Canntab's CEO.

"Canntab has continued to work diligently to build shareholder value during this crisis as we are designated an essential business. Signing our first purchase order with a quality partner having a global reach such as MediPharm is simply the tip of the iceberg for Canntab."

The orders will be a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths.

The tablets will be sold in the coming months to medical and adult-use consumers across Canada, via licensed provincial dispensaries.

Canntab has already filed its 60-day notice for approval to sell the instant release products with Health Canada and expects that its tablets will be available for sale in the early summer.

The company is currently the only company in Canada capable of delivering THC, CBD and/or any combination THC/CBD in pharmaceutical-grade tablets or hard pills.

Shares surged 12.24% in Toronto to C$1.10.

---Updates for share price---

Contact the author at [email protected]

Quick facts: Canntab Therapeutics Ltd

Price: 0.7 CAD

CSE:PILL
Market: CSE
Market Cap: $22.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.  Goldstein discusses how the...

on 06/02/2020

2 min read